With fresh FDA nod, Servier branches targeted drug Tibsovo into bile duct cancer

As Servier moves targeted cancer drug Tibsovo closer to earlier treatment of acute myeloid leukemia—and eyes a potential competitor, too—the French drugmaker has picked up a smaller use along the way.